Citadel Advisors
YARW

Citadel Advisors’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Citadel Advisors’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$60 – 15593
2022
Q4 		– Hold
0
– – – 14780
2022
Q3 		– Sell
-51
Closed -$18K – 13708
2022
Q2 		$18K Sell
51
-66
-56% -$27.7K ﹤0.01% 12442
2022
Q1 		$69K Buy
117
+23
+24% +$13.7K ﹤0.01% 12590
2021
Q4 		$86K Buy
94
+46
+96% +$49.4K ﹤0.01% 12861
2021
Q3 		$60K Buy
48
+11
+30% +$21.3K ﹤0.01% 13268
2021
Q2 		$116K Sell
37
-30
-45% -$119K ﹤0.01% 12780
2021
Q1 		$415K Buy
+67
New +$486K ﹤0.01% 10089

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's YARW Position: Q1 2026 in Review

Citadel Advisors increased its Yarrow Bioscience, Inc. Common Stock (YARW) stake by 1,584% in Q1 2026, buying an estimated $282K and bringing the position to 10,289 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #10418.

Citadel Advisors first reported a position in YARW in Q1 2018 and has held it in 20 quarters since. The position peaked at $4.12M in Q4 2024. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • Citadel Advisors held 10,289 shares of Yarrow Bioscience, Inc. Common Stock worth $307K as of Q1 2026.
  • Citadel Advisors bought 9,678 Yarrow Bioscience, Inc. Common Stock shares in Q1 2026, an estimated $282K.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10418 holding.
  • Citadel Advisors first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and has held it in 20 quarters since.
  • Citadel Advisors's Yarrow Bioscience, Inc. Common Stock position peaked at $4.12M in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.